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Introduction 
With the death of more than three million people 
around the world, the need to develop effective 
vaccines capable of controlling the virus that caused the 
pandemic of COVID-19 was realized to ensure the safety 
of the population through the immunity developed 
[1].To start the process, scientists released the genetic 
sequence of the virus in January 2020, thus, researchers 
used new platforms of vaccine technology in order to 
develop an effective vaccine against the pathology, 
however, the first vaccine started clinical trials in 
humans in March 2020, being considered one of the 
fastest vaccine development programs in history [2,3].  
Several production technologies have been 
evaluated, among them: viral vaccines (inactivated or 
attenuated), nucleic acids (DNA and RNA), protein 
vaccines (recombinant or VLP) and those that use viral 
vectors (replicating or non-replicating) [4]. However, 
the vaccines studied for COVID-19 aim to induce 
neutralizing antibodies against viral subunits, 
containing, most of them, as a target, the RBD region 
preventing the virus uptake by the human ACE2 
receptor [5]. 
To produce a vaccine it is necessary to follow the 
phases of clinical study, in general, animal models, to 
evaluate the dose and the level of toxicity in this 
population. However, clinical trials in humans need to 
go through three stages, namely: safety of the product; 
evaluation of immunogenicity, dose and frequency of 
administration; and the efficacy of the product involving 
volunteers. After going through this process, involving 
the publication of scientific data involved in the 
research, the vaccine in question is submitted for 
evaluation by regulatory agencies, so that it can then be 
produced and distributed to the population. Finally, 
post-approval studies aim to analyze the possible effects 
and adverse events after the application of the vaccine 
in large quantities in the target population [6]. However, 
this entire process is estimated to take months to years, 
but the development of the COVID-19 vaccine was 
performed within a period of approximately 18 months, 
which calls into question its efficacy and safety [7]. 
Among all the aforementioned types of vaccines, 
those that most caused adverse effects were the mRNA 
vaccines, and their benefit was questioned by studies 
on their safety and efficacy that were carried out in 
thousands of volunteers, showing a 95% rate for the 
BNT162b2 mRNA vaccine [8], and a 94% rate for the 
mRNA-1273 SARS-CoV-2 vaccine 9. The mRNA 
vaccines, Pfizer and Moderna, showed adverse events 
after the second dose, especially after researchers were 
alerted to evidence of a relevant number of people who 
developed heart diseases, such as myocarditis and 
pericarditis; however, these data are reports from other 
countries, since these vaccines have only recently 
arrived in Brazil [9]. 
However, the Vaccine Adverse Event Reporting 
System (VAERS) has reported the development of 
myocarditis after doses administered to persons under 
30 years of age. In addition, the mRNA vaccine has been 
authorized for use in children between 12 and 15 years 
of age, but there have been no reports in this age group. 
In a comparative study, among the cases of myocarditis 
after vaccination, a higher prevalence was noted in 
males between 18 and 30 years of age. Another system 
that tracks adverse events in hospitals, the Vaccine 
Safety Datalink, noted that inflammation was more 
likely after the second dose of vaccine, thus, reported 
in a case of seven adolescents who developed 
myocarditis 4 days after the second dose [10]. 
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other cardiovascular diseases after infection with the 
virus that causes COVID-19 besides myocarditis, such 
as arrhythmia, heart failure, AMI, cardiac arrest, and 
cases of myocardial lesions with increased troponin I 
[11,12,13] were found. However, regarding adverse 
events caused after COVID-19 vaccination of vaccines 
using mRNA, there were no reports of cardiovascular 
diseases other than myocarditis, which was prevalent, 
and pericarditis. However, mRNA vaccines, such as 
Pfizer and Moderna, have included cardiopathies during 
their studies, reporting such efficacy for the group under 
discussion. The effects caused were local and less 
common in the elderly, and during the vaccine 
evaluation period, they noted that cardiovascular effects 
had a frequency of less than 0.1% [14,15,16].  
Thus, this review study aimed to analyze the 
efficacy of mRNA vaccines and their adverse events. 
 
Methods 
This is a Systematic Literature Review, with a 
search conducted through the electronic platforms 
Pubmed, Scielo, Google Acadêmico, and LILACS (Latin 
American and Caribbean Literature on Health Sciences), 
between the years 2020 and 2021. The descriptors 
''Vaccine'', ''mRNA'', ''COVID-19'', and ''Coronavirus'' 
were used, associated with the Boolean operator ''AND'' 
as the only crossing strategy. A total of 143 articles were 
found and 14 were selected. Among the inclusion 
criteria were texts available in full, without language 
restriction, with publication date from 2020 to 2021. 
Texts not corresponding to the delimited period, 
duplicates and articles that did not address the thematic 
proposal were excluded. 
 
Results and Discussion 
More than 12 million doses were administered to 
16- to 24-year-olds; among these, 275 people 
developed myocarditis after vaccination in this age 
group; in addition, 475 cases were in people younger 
than 30 years of age. The vaccines that caused this 
event are mRNA, Pfizer and Moderna. In addition, Pfizer 
has been authorized for application in children between 
12 and 15 years of age, but data for this age group are 
not yet available. The incidence of myocarditis after 
vaccination was 50 cases per million for men aged 18 to 
30 years [16]. Another system that tracks adverse 
events in hospitals, the Vaccine Safety Datalink, showed 
no reports of heart inflammation above the numbers 
typically seen in the population, but it did show that 
inflammation was more likely after a second dose of 
vaccine. This condition appeared to be more common in 
young people and male individuals than in women and 
the elderly, and may occur in 16 people out of every 1 
million who received both doses of the vaccine [17]. The 
individuals who presented myocarditis achieved a quick 
recovery, considering that three of them needed to be 
admitted to the Intensive Care Unit, among those cases 
analyzed, 81% showed improvement of the condition 
and 19% had symptoms until the moment. Another 
study revealed seven cases of myocarditis reported in a 
hospital in Oregon, USA, involving male patients 
belonging to the age group of 14 to 19 years old; this 
case developed approximately four days after the 
application of mRNA vaccine; furthermore, there was no 
evidence of infection in the acute phase by SARS-coV-2; 
however, after treatment, all were discharged from the 
hospital and none required ICU admission [9]. 
 
Conclusion 
The vaccines under analysis were 95% effective; 
however, they showed adverse events after the second 
dose, such as myocarditis. Thus, there was an increase 
in reports of myocarditis in male patients and young 
people who received mRNA vaccine, which cast doubts 
on the safety and efficacy of these vaccines. However, 
there are still few reports of myocarditis after 
vaccination because some countries do not report or 
publish the data and other countries do not apply the 
vaccines in question for the time being. However, it is 
necessary to have the agencies responsible for notifying 
these adverse effects to have available data that can 
prove or disprove the relationship of the application of 
these vaccines with the development of pathologies 
after COVID-19 vaccination. 
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